F M Investments LLC Acquires New Position in NovoCure Limited (NASDAQ:NVCR)

F M Investments LLC acquired a new stake in shares of NovoCure Limited (NASDAQ:NVCR - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 32,100 shares of the medical equipment provider's stock, valued at approximately $957,000.

Several other large investors also recently bought and sold shares of the business. Emerald Advisers LLC purchased a new stake in shares of NovoCure during the 4th quarter valued at about $16,317,000. Franklin Resources Inc. grew its position in NovoCure by 222.6% in the 3rd quarter. Franklin Resources Inc. now owns 180,853 shares of the medical equipment provider's stock worth $2,904,000 after purchasing an additional 124,793 shares during the period. Cinctive Capital Management LP purchased a new stake in NovoCure during the 4th quarter valued at $3,272,000. C WorldWide Group Holding A S lifted its holdings in shares of NovoCure by 19.2% during the 4th quarter. C WorldWide Group Holding A S now owns 621,784 shares of the medical equipment provider's stock valued at $18,529,000 after buying an additional 100,000 shares during the period. Finally, Invesco Ltd. boosted its stake in shares of NovoCure by 72.6% in the 4th quarter. Invesco Ltd. now owns 189,474 shares of the medical equipment provider's stock worth $5,646,000 after buying an additional 79,698 shares during the last quarter. 84.61% of the stock is currently owned by institutional investors.

NovoCure Trading Down 3.8 %

Shares of NASDAQ NVCR traded down $0.63 during trading hours on Wednesday, hitting $15.83. 760,635 shares of the company traded hands, compared to its average volume of 1,183,657. The company has a current ratio of 1.49, a quick ratio of 1.44 and a debt-to-equity ratio of 0.27. The company's 50 day moving average price is $19.31 and its 200 day moving average price is $21.57. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -11.31 and a beta of 0.65. NovoCure Limited has a 12 month low of $11.70 and a 12 month high of $34.13.

Remove Ads

NovoCure (NASDAQ:NVCR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.27). NovoCure had a negative return on equity of 41.48% and a negative net margin of 25.93%. The firm had revenue of $161.27 million for the quarter, compared to analysts' expectations of $161.30 million. On average, equities research analysts anticipate that NovoCure Limited will post -1.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on NVCR shares. JPMorgan Chase & Co. reduced their price objective on NovoCure from $29.00 to $28.00 and set a "neutral" rating for the company in a research report on Thursday, April 10th. StockNews.com cut NovoCure from a "hold" rating to a "sell" rating in a report on Wednesday, April 9th. HC Wainwright restated a "buy" rating and issued a $38.00 price target on shares of NovoCure in a research report on Tuesday, January 14th. Finally, Wedbush cut their price objective on NovoCure from $29.00 to $27.00 and set a "neutral" rating for the company in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. According to MarketBeat, NovoCure presently has a consensus rating of "Hold" and a consensus target price of $34.17.

NovoCure Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.